CJC-1295 (long-acting GHRH analog) activation of the GH/IGF-1 axis produced measurable serum protein profile changes in healthy adults, revealing systemic metabolic effects beyond just hormone elevation.
Key findingCJC-1295 (long-acting GHRH analog) activation of the GH/IGF-1 axis produced measurable serum protein profile changes in healthy adults, revealing syst
What the researchers found
CJC-1295 (long-acting GHRH analog) activation of the GH/IGF-1 axis produced measurable serum protein profile changes in healthy adults, revealing systemic metabolic effects beyond just hormone elevation.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 19(6), 471-7
Citation
Sackmann-Sala, Lucila; Ding, Juan; Frohman, Lawrence A; Kopchick, John J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 19(6), 471-7. https://doi.org/10.1016/j.ghir.2009.03.001